Is fluorescein-guided technique able to help in resection of high-grade gliomas?

Francesco Acerbi, Morgan Broggi(Fondazione IRCCS Istituto Neurologico Carlo Besta), Marica Eoli(Molecular Oncology (United States)), Elena Anghileri(Molecular Oncology (United States)), Claudio Cavallo(Fondazione IRCCS Istituto Neurologico Carlo Besta), Carlo Boffano(Fondazione IRCCS Istituto Neurologico Carlo Besta), Roberto Cordella(Fondazione IRCCS Istituto Neurologico Carlo Besta), Lucia Cuppini(Molecular Oncology (United States)), Bianca Pollo(Fondazione IRCCS Istituto Neurologico Carlo Besta), Marco Schiariti(Fondazione IRCCS Istituto Neurologico Carlo Besta), Sergio Visintini(Fondazione IRCCS Istituto Neurologico Carlo Besta), Chiara Orsi(University of Pavia), Emanuele La Corte(Fondazione IRCCS Istituto Neurologico Carlo Besta), Giovanni Broggi(Fondazione IRCCS Istituto Neurologico Carlo Besta), Paolo Ferroli(Fondazione IRCCS Istituto Neurologico Carlo Besta)
Neurosurgical FOCUS
February 1, 2014
Cited by 162Open Access
Full Text

Abstract

OBJECT: Fluorescein, a dye that is widely used as a fluorescent tracer, accumulates in cerebral areas where the blood-brain barrier is damaged. This quality makes it an ideal dye for the intraoperative visualization of high-grade gliomas (HGGs). The authors report their experience with a new fluorescein-guided technique for the resection of HGGs using a dedicated filter on the surgical microscope. METHODS: The authors initiated a prospective Phase II trial (FLUOGLIO) in September 2011 with the objective of evaluating the safety of fluorescein-guided surgery for HGGs and obtaining preliminary evidence regarding its efficacy for this purpose. To be eligible for participation in the study, a patient had to have suspected HGG amenable to complete resection of the contrast-enhancing area. The present report is based on the analysis of the short- and long-term results in 20 consecutive patients with HGGs (age range 45-74 years), enrolled in the study since September 2011. In all cases fluorescein (5-10 mg/kg) was injected intravenously after intubation. Tumor resection was performed with microsurgical technique and fluorescence visualization by means of BLUE 400 or YELLOW 560 filters on a Pentero microscope. RESULTS: The median preoperative tumor volume was 30.3 cm(3) (range 2.4-87.8 cm(3)). There were no adverse reactions related to fluorescein administration. Complete removal of contrast-enhanced tumor was achieved in 80% of the patients. The median duration of follow-up was 10 months. The 6-months progression-free survival rate was 71.4% and the median survival was 11 months. CONCLUSIONS: Analysis of these 20 cases suggested that fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and allows a high rate of complete resection of contrast-enhanced tumor as determined on early postoperative MRI. Clinical trial registration no.: 2011-002527-18 (EudraCT).


Related Papers

No related papers found

Powered by citation graph analysis